Pharmacotherapy of hormone refractory prostate cancer: New developments and challenges

Eli Rosenbaum, Michael A Carducci

Research output: Contribution to journalArticle

Abstract

Hormone refractory prostate cancer (HRPC) remains a challenge in the management of prostate cancer patients. With the widespread use of PSA (prostate specific antigen), recurrent disease after local treatment for localised prostate cancer is usually diagnosed long before evidence of metastatic disease. In many cases, hormonal manipulations are started at the time of biochemical relapse and therefore, patients become 'hormone refractory' earlier in the course of their disease, frequently with a good performance status, often with no evidence of metastatic disease, and they still face a considerably long life expectancy. Despite these changes, the need for more options in the treatment of HRPC is obvious. The pharmacological treatments that are in use and those that are under investigation for this group of patients will be discussed and include: cytotoxic agents including the microtubule inhibitors, alone and in combination with other conventional or experimental therapies such as calcitriol or thalidomide; treatment with epothilone analogues; endothelin receptor antagonists; palliative therapy with bisphosphonates, bone-targeted radiopharmaceuticals and other developing treatments such as vaccines, gene therapies and monoclonal antibodies.

Original languageEnglish (US)
Pages (from-to)875-887
Number of pages13
JournalExpert Opinion on Pharmacotherapy
Volume4
Issue number6
DOIs
StatePublished - Jun 1 2003

Fingerprint

Prostatic Neoplasms
Hormones
Drug Therapy
Epothilones
Therapeutics
Active Immunotherapy
Investigational Therapies
Thalidomide
Radiopharmaceuticals
Calcitriol
Cytotoxins
Diphosphonates
Prostate-Specific Antigen
Life Expectancy
Palliative Care
Microtubules
Genetic Therapy
Monoclonal Antibodies
Pharmacology
Bone and Bones

Keywords

  • Chemotherapy
  • Docetaxel
  • Endothelin receptor
  • Prostate cancer
  • Vaccines

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacotherapy of hormone refractory prostate cancer : New developments and challenges. / Rosenbaum, Eli; Carducci, Michael A.

In: Expert Opinion on Pharmacotherapy, Vol. 4, No. 6, 01.06.2003, p. 875-887.

Research output: Contribution to journalArticle

@article{e9c5ecbfd4d1456b80e0313bf81e4c61,
title = "Pharmacotherapy of hormone refractory prostate cancer: New developments and challenges",
abstract = "Hormone refractory prostate cancer (HRPC) remains a challenge in the management of prostate cancer patients. With the widespread use of PSA (prostate specific antigen), recurrent disease after local treatment for localised prostate cancer is usually diagnosed long before evidence of metastatic disease. In many cases, hormonal manipulations are started at the time of biochemical relapse and therefore, patients become 'hormone refractory' earlier in the course of their disease, frequently with a good performance status, often with no evidence of metastatic disease, and they still face a considerably long life expectancy. Despite these changes, the need for more options in the treatment of HRPC is obvious. The pharmacological treatments that are in use and those that are under investigation for this group of patients will be discussed and include: cytotoxic agents including the microtubule inhibitors, alone and in combination with other conventional or experimental therapies such as calcitriol or thalidomide; treatment with epothilone analogues; endothelin receptor antagonists; palliative therapy with bisphosphonates, bone-targeted radiopharmaceuticals and other developing treatments such as vaccines, gene therapies and monoclonal antibodies.",
keywords = "Chemotherapy, Docetaxel, Endothelin receptor, Prostate cancer, Vaccines",
author = "Eli Rosenbaum and Carducci, {Michael A}",
year = "2003",
month = "6",
day = "1",
doi = "10.1517/14656566.4.6.875",
language = "English (US)",
volume = "4",
pages = "875--887",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Pharmacotherapy of hormone refractory prostate cancer

T2 - New developments and challenges

AU - Rosenbaum, Eli

AU - Carducci, Michael A

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Hormone refractory prostate cancer (HRPC) remains a challenge in the management of prostate cancer patients. With the widespread use of PSA (prostate specific antigen), recurrent disease after local treatment for localised prostate cancer is usually diagnosed long before evidence of metastatic disease. In many cases, hormonal manipulations are started at the time of biochemical relapse and therefore, patients become 'hormone refractory' earlier in the course of their disease, frequently with a good performance status, often with no evidence of metastatic disease, and they still face a considerably long life expectancy. Despite these changes, the need for more options in the treatment of HRPC is obvious. The pharmacological treatments that are in use and those that are under investigation for this group of patients will be discussed and include: cytotoxic agents including the microtubule inhibitors, alone and in combination with other conventional or experimental therapies such as calcitriol or thalidomide; treatment with epothilone analogues; endothelin receptor antagonists; palliative therapy with bisphosphonates, bone-targeted radiopharmaceuticals and other developing treatments such as vaccines, gene therapies and monoclonal antibodies.

AB - Hormone refractory prostate cancer (HRPC) remains a challenge in the management of prostate cancer patients. With the widespread use of PSA (prostate specific antigen), recurrent disease after local treatment for localised prostate cancer is usually diagnosed long before evidence of metastatic disease. In many cases, hormonal manipulations are started at the time of biochemical relapse and therefore, patients become 'hormone refractory' earlier in the course of their disease, frequently with a good performance status, often with no evidence of metastatic disease, and they still face a considerably long life expectancy. Despite these changes, the need for more options in the treatment of HRPC is obvious. The pharmacological treatments that are in use and those that are under investigation for this group of patients will be discussed and include: cytotoxic agents including the microtubule inhibitors, alone and in combination with other conventional or experimental therapies such as calcitriol or thalidomide; treatment with epothilone analogues; endothelin receptor antagonists; palliative therapy with bisphosphonates, bone-targeted radiopharmaceuticals and other developing treatments such as vaccines, gene therapies and monoclonal antibodies.

KW - Chemotherapy

KW - Docetaxel

KW - Endothelin receptor

KW - Prostate cancer

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=0038347227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038347227&partnerID=8YFLogxK

U2 - 10.1517/14656566.4.6.875

DO - 10.1517/14656566.4.6.875

M3 - Article

C2 - 12783585

AN - SCOPUS:0038347227

VL - 4

SP - 875

EP - 887

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 6

ER -